Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulindac and Tamoxifen for Desmoid Tumors
NCT00068419Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Feb 2004
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sulindac and tamoxifen in desmoid tumor, sponsored by Children's Oncology Group. Primary endpoints: Percentage of Patients Failure Free at 2 Years Following Study Entry and Percentage of Patients Experiencing a Grade 3 or Higher Adverse Event During Therapy at 12 months. Started Feb 2004; status: completed.
02
Drugs
sulindactamoxifen
03
Conditions
desmoid tumor
Beyond the preview
Go deeper on NCT00068419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00068419.